FDA Final Rule on Postmarket Safety Reporting for Combination Products Understanding the FDA Final Rule on Postmarket Safety Reporting for Combination Products The FDA’s regulatory framework for combination products has evolved significantly over the years. The recent Final Rule that addresses postmarket safety reporting requirements is a critical component for organizations involved in the development, manufacture, and marketing of these products. This article provides a step-by-step tutorial guide to navigating the complexities of this rule, focusing on actionable items for regulatory professionals and teams. Step 1: Understanding the Regulatory Framework The first step in complying with the FDA Final Rule…

CDRH IDE + CDER IND: Parallel Review Considerations CDRH IDE + CDER IND: Parallel Review Considerations The integration of drug and diagnostic development has gained substantial momentum, leading to regulatory pathways such as the CDRH Investigational Device Exemption (IDE) and the CDER Investigational New Drug (IND). The parallel review of these submissions by the FDA offers a streamlined approach, but it involves a complex regulatory framework. This guide serves as a step-by-step tutorial, detailing actionable items for understanding the process, essential documentation, and interactions with the FDA for combination products. This thorough examination of the CDRH IDE and CDER IND…

Bridging CDER/CBER Drug Data With CDRH Device Performance Data Bridging CDER/CBER Drug Data With CDRH Device Performance Data This comprehensive guide aims to outline the step-by-step process of effectively bridging drug data from the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) with device performance data from the Center for Devices and Radiological Health (CDRH). Understanding this process is crucial for regulatory professionals working on combination products as per FDA guidelines. Step 1: Understanding Combination Products Combination products are therapeutic and diagnostic products that combine a drug, device, and/or biological product. As…

510(k) Clearance for Combination Products With Existing Devices 510(k) Clearance for Combination Products With Existing Devices The regulatory landscape for combination products, particularly those leveraging existing devices, requires a nuanced understanding of the FDA’s pathways and requirements. This tutorial offers a sequential guide intended for regulatory affairs professionals, quality assurance experts, and commercial teams navigating the challenges of obtaining 510(k) clearance for combination products. The focus is geared towards US-based processes, adhering to FDA guidelines. Step 1: Understanding Combination Products and Regulatory Classification Combination products consist of a combination of a drug, device, and/or biological product. The FDA Office of…

Impact of REMS on Combination Product Labeling at FDA Impact of REMS on Combination Product Labeling at FDA The increasing complexity of combination products necessitates an understanding of the regulatory framework governing them. This guide focuses on Risk Evaluation and Mitigation Strategies (REMS) and their impact on labeling for combination products regulated by the FDA, particularly by its Office of Combination Products (OCP), the Center for Drug Evaluation and Research (CDER), and the Center for Devices and Radiological Health (CDRH). This step-by-step guide aims to provide actionable insights for regulatory affairs professionals engaged in FDA combination product consulting. Step 1:…

Case Example: Auto-Injector Review Pathway Under FDA Guidance Case Example: Auto-Injector Review Pathway Under FDA Guidance In the evolving landscape of healthcare, the regulatory pathway for combination products such as auto-injectors is paramount for safe and effective patient use. This article presents a comprehensive, step-by-step tutorial on navigating the review pathway under FDA guidance. The focus on FDA combination product consulting will provide professionals with actionable insights for successful submissions. Step 1: Understanding the Definition and Categories of Combination Products The first step in the regulatory pathway for an auto-injector is understanding what constitutes a combination product under FDA regulations….

FDA OCP (Office of Combination Products) Engagement Strategy in 2023: Pre-Sub to Designation FDA OCP (Office of Combination Products) Engagement Strategy in 2023: Pre-Sub to Designation In 2023, the regulatory landscape for combination products continues to evolve, necessitating a comprehensive strategy for their development and submission. The FDA’s Office of Combination Products (OCP) plays a critical role in determining the regulatory pathway for these products, which can involve both drug and device components. This tutorial guide walks professionals in the pharmaceutical and clinical research fields through essential steps needed to effectively engage with the OCP, from the initial pre-submission stage…

Single vs Dual Application Strategy: NDA/BLA With Device Info vs Separate PMA/510(k) in 2024 Single vs Dual Application Strategy: NDA/BLA With Device Info vs Separate PMA/510(k) in 2024 In the pharmaceutical and medical device industries, understanding the correct regulatory pathway is crucial for strategic planning and successful product launch. This in-depth guide focuses on the Single vs Dual Application Strategy when dealing with combination products in a US context. The insights provided will allow regulatory affairs professionals, quality assurance teams, and commercial stakeholders to navigate the complexities associated with New Drug Applications (NDA), Biologic License Applications (BLA), Premarket Approval (PMA),…

Mapping 505(b)(2) + Device Pathways: US Combination Product Strategy in 2023 Mapping 505(b)(2) + Device Pathways: US Combination Product Strategy in 2023 The intersection of drug and device regulation has become increasingly complex as the healthcare landscape evolves. With the introduction of combination products, understanding the regulatory pathways to navigate effectively becomes essential for industry professionals. This tutorial provides a step-by-step guide to the FDA’s 505(b)(2) application process combined with device pathways, specifically designed for regulatory affairs and clinical operations teams. Each section will detail practical actions necessary for compliance, ensuring a comprehensive understanding of FDA combination product consulting. Step…

Cross-Center Consultation Playbook: CDER/CBER/CDRH Review Alignment in 2023 Cross-Center Consultation Playbook: CDER/CBER/CDRH Review Alignment in 2023 In the complex landscape of drug-device submissions, understanding the interplay between the FDA’s different centers is essential for regulatory professionals. This article serves as a comprehensive step-by-step guide that outlines actionable strategies for achieving effective alignment between the Center for Drug Evaluation and Research (CDER), the Center for Biologics Evaluation and Research (CBER), and the Center for Devices and Radiological Health (CDRH) in the context of combination products. The focus of this guide is to ensure compliance with regulatory paths while simultaneously simplifying the…